News

As per terms of the deal, MedImmune will exclusively develop bi-specific and multi-specific antibody products derived from a Compugen pipeline program. The exclusive license will allow MedImmune to

The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified. The ATTR-ACT study was designed to assess

The approval is for patients whose minimal residual disease (MRD) is greater than or equal to 0.1 percent. This indication is approved under accelerated approval based on MRD

The company said it will stop trial based on significant positive results from interim analysis. According to the company, the MN-001 significantly reduced mean serum triglycerides, which is a

Redx said it communicated with the Medicines and Healthcare products Regulatory Agency (MHRA) to interrupt the clinical trial of the Porcupine inhibitor. The company detected significant adverse events

Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload. Actinium will also be responsible

bluebird bio corporate development and strategy oncology franchise leader and senior vice president Joanne Smith-Farrell said: "Entering into this co-development and co-promotion partnership with Celgene is a significant

Takeda announced that its consideration of such an offer is at a preliminary and exploratory stage and no approach has been made to the board of Shire. Shire

Daiichi Sankyo R&D Division Oncology Function head, executive officer Koichi Akahane said: "There are no HER2-targeting treatment options currently available for patients with HER2-positive gastric cancer whose tumors